combine@alvar.ug

HBV seroepidemiology data for Africa provides insights into transmission and prevention

HBV seroepidemiology data for Africa provides insights into transmission and prevention

Show simple record

dc.contributor.author Anna L. McNaughton
dc.contributor.author José Lourenço
dc.contributor.author Phillip Armand Bester
dc.contributor.author Jolynne Mokaya
dc.contributor.author Sheila F Lumley
dc.contributor.author Donall Forde
dc.contributor.author Tongai G. Maponga
dc.contributor.author Kenneth R. Katumba
dc.contributor.author Dominique Goedhals
dc.contributor.author Sunetra Gupta
dc.contributor.author Janet Seely
dc.contributor.author Robert Newton
dc.contributor.author Ponsiano Ocama
dc.contributor.author Philippa C. Matthews
dc.date.accessioned 2021-01-11T13:51:44Z
dc.date.available 2021-01-11T13:51:44Z
dc.date.issued 2019
dc.identifier.uri https://combine.alvar.ug/handle/1/49520
dc.description.abstract International goals for elimination of hepatitis B virus (HBV) infection set ambitious targets for 2030. In many African populations, HBV prevalence remains high ([≥]8%) despite the roll-out of infant HBV immunisation from the mid-1990s onwards. Enhanced efforts are now urgently required to improve an understanding of population epidemiology, in order to determine which interventions are most likely to be effective in advancing populations towards elimination goals. In populations with a high prevalence of infection, catch-up HBV vaccination of adults has sometimes been deployed as a preventive strategy. An alternative approach of test and treat could be applied as a tool to interrupt transmission. We used a systematic approach to investigate the relationship between prevalence of HBV infection (HBsAg) and exposure (anti-HBc) in Africa, and then applied a mathematical model to investigate the impact of catch-up vaccination and a test and treat strategy in Uganda, representing a high prevalence setting. We demonstrate a strong relationship between the prevalence of HBsAg and anti-HBc (p<0.0001), but with region-specific differences that may reflect different patterns of transmission. In high prevalence settings, catch-up vaccination may have a transient effect but this intervention does not contribute to a sustained decline in prevalence. In contrast, diagnosing and treating infection has a marked impact on reducing prevalence, equivalent to that of infant immunisation. Conclusion: We have developed a high-resolution picture of HBV epidemiology across Africa. Developing insights into regional differences provides an evidence base for the most effective interventions. In combination with robust neonatal immunisation programmes, testing and treating infection is likely to be of most impact in making advances towards elimination targets.
dc.publisher Cold Spring Harbor Laboratory
dc.title HBV seroepidemiology data for Africa provides insights into transmission and prevention
dc.type Preprint
dc.identifier.doi 10.1101/654061
dc.identifier.mag 2947197999
dc.identifier.lens 041-812-637-669-600
dc.identifier.spage 654061
dc.subject.lens-fields Epidemiology
dc.subject.lens-fields Vaccination
dc.subject.lens-fields Psychological intervention
dc.subject.lens-fields HBsAg
dc.subject.lens-fields Hepatitis B virus
dc.subject.lens-fields Population
dc.subject.lens-fields High prevalence
dc.subject.lens-fields Transmission (mechanics)
dc.subject.lens-fields Medicine
dc.subject.lens-fields Environmental health


This record appears in the collections of the following institution(s)

Show simple record

Search Entire Database


Browse

My Account